Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy
Kidney Diseases · 2022 · 8 (1) · 26-43
DOI: 10.1159/000518664 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney Diseases, online erschienen am 28.09.2021. Verfasst von Lin Tian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, China. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Cells of the immune system can inhibit tumor growth and progression; however, immune cells can also promote tumor cell growth, survival, and angiogenesis as a result of the immunosuppressive microenvironments. In the last decade, a growing number of new therapeutic strategies focused on reversing the immunosuppressive status of tumor microenvironments (TMEs), to reprogram the TME to be normal, and to further activate the antitumor functions of immune cells. Most of the “hot tumors” are encompassed with M2 macrophages promoting tumor growth, and the accumulation of M2 macrophages into tumor islets leads to poor prognosis in a wide variety of tumors. Summary: Therefore, how to uncover more immunosuppressive signals and to reverse the M2 tumor-associated macrophages (TAMs) to M1-type macrophages is essential for reversing the immunosuppressive state. Except for reeducation of TAMs in the cancer immunotherapy, macrophages as central effectors and regulators of the innate immune system have the capacity of phagocytosis and immune modulation in macrophage-based cell therapies. Key Messages: We review the current macrophage-based cell therapies that use genetic engineering to augment macrophage functionalities with antitumor activity for the application of novel genetically engineered immune cell therapeutics. A combination of TAM reeducation and macrophage-based cell strategy may bring us closer to achieving the original goals of curing cancer. In this review, we describe the characteristics, immune status, and tumor immunotherapy strategies of macrophages to provide clues and evidences for future macrophage-based immune cell therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, China.
- Institute of Hematology, Zhejiang University, Hangzhou, China.
- Department of Medical Oncology, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University, Shulan International Medical College, Hangzhou, China.
- Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China.
Zitieren
APA
Tian, L., Lei, A., Tan, T., Zhu, M., Zhang, L., Mou, H., & Zhang, J. (2022). Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy. Kidney Diseases, 8(1), 26-43. https://doi.org/10.1159/000518664
Vancouver
Tian L, Lei A, Tan T, Zhu M, Zhang L, Mou H, et al. Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy. Kidney Diseases. 2022;8(1):26-43. doi:10.1159/000518664
BibTeX
@article{Tian2022,
author = {Tian, Lin and Lei, Anhua and Tan, Tianyu and Zhu, Mengmeng and Zhang, Li and Mou, Haibo and Zhang, Jin},
title = {Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy},
journal = {Kidney Diseases},
year = {2022},
volume = {8},
number = {1},
pages = {26--43},
doi = {10.1159/000518664}
}
EUVIMED